Comparative Pharmacology
Head-to-head clinical analysis: ARISTOCORT A versus FLOVENT DISKUS 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOCORT A versus FLOVENT DISKUS 50.
ARISTOCORT A vs FLOVENT DISKUS 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, suppress cytokine production, and decrease inflammation and immune responses.
Glucocorticoid receptor agonist; anti-inflammatory transcription factor modulation; inhibits phospholipase A2, reduces arachidonic acid release, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and inflammatory cell migration.
Intralesional injection: 2.5-5 mg per lesion, repeated every 1-2 weeks. Topical: Apply thin film to affected area 2-4 times daily.
1 inhalation (50 mcg) twice daily, administered via oral inhalation.
None Documented
None Documented
Terminal half-life: 2-3 hours for triamcinolone acetonide. Clinical context: Duration of action longer due to receptor binding and intracellular activity; anti-inflammatory effects persist 24-48 hours after IM administration.
Terminal elimination half-life is approximately 14-17.5 hours; this supports once- or twice-daily dosing in asthma maintenance.
Renal: 75% as metabolites (primarily conjugated), 15% as unchanged drug. Biliary/fecal: 10%.
Primarily fecal (87-90%) after hepatic metabolism; renal excretion accounts for <5% as unchanged drug and metabolites.
Category C
Category C
Corticosteroid
Corticosteroid